AstraZeneca reports top-line results from the Brilinta EUCLID trial in patients with peripheral artery disease

Click here to view online. Add this email to your safelist.

4 October 2016

AstraZeneca today announced top-line results from the EUCLID trial. Brilinta (ticagrelor) did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease (PAD) patient population and therefore did not meet the primary endpoint of the trial.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.